When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
Though there are channels through which terminally ill patients can access some experimental drugs that have not yet received FDA approval for marketing to the public, in general those drugs must already be proven safe and effective.
This month theme issue editor, Trahern Jones, a fourth-year student at Mayo Medical School in Rochester, Minnesota, spoke with Dr. Edward Laskowski about the use of performance-enhancing drugs and substances among athletes today.
Arguments that mistrust about information security will deter patients from embracing telehealth care ignore patients' willingness to take on risk in the pursuit of health benefits and the role physicians will play in encouraging adoption.
Patients’ personal or cultural views toward illness, the business of health care under which we all operate, and our own personal opinions about the ideal of health and wellness can all compromise pain treatment. It is our responsibility to see that it does not.
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
Patients who have been encouraged to think of themselves as consumers and a medical system that is driven by individual demands rather than big-picture planning can undermine fairness in the distribution of vaccines.
Physicians are not obligated to offer testing or treatments that are not medically indicated—even if patients demand them. This does not mean, however, that a physician should be dismissive of the patient’s concerns.
Jessie Kimbrough-Sugick, MD, MPH, Jessica Holzer, MA, and Eric B. Bass, MD, MPH
Researchers who approach community partners with an agenda already in hand are missing the point of the community-based participatory research enterprise: developing priorities for study together.